Aerska, which uses brain shuttle technology to deliver RNAi therapeutics to the brain, announced the close of a $39 million Series A financing round, bringing its total funding to $60 million. EQT ...
Novartis has agreed to pay up to $1.7 billion to license an experimental Alzheimer’s therapy from China-based SciNeuro, a megadeal that signals how aggressively big pharma is now chasing ...
Parkinson’s disease and multiple system atrophy are members of a class of devastating neurodegenerative diseases called synucleinopathies, which are characterized by the presence of alpha-synuclein (α ...
DUBLIN and LONDON, 15 June 2026 -- Aerska, a biotechnology company using brain shuttle technology to develop RNA medicines for CNS diseases, today announces the appointment of Itziar Canamasas and Uli ...
The highly selective border lining the brain’s vasculature is the Achilles’ heel of any large therapeutic molecule aiming for targets in the brain, anti-Aβ antibodies included. Not only do fewer than ...
Hello, everyone. I'm Pete Stavropoulos biotech analyst at Cantor and welcome to our first of 2 webinars with Voyager to discuss its blood-brain barrier crossing technologies. It's an exciting time for ...
Hello, everyone. I'm Pete Stavropoulos, biotech analyst at Cantor with another webinar on the blood-brain barrier crossing technologies. It's an exciting time for the field. The blood-brain barrier ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results